Publications

Cytochrome P450 Enzymes Involved in Metoprolol Metabolism and Use of Metoprolol as a CYP2D6 Phenotyping Probe Drug

Berger B, Bachmann F, Duthaler U, Krähenbühl S, Haschke M

Frontiers in Pharmacology,  24 Jul 2018


Recommendation on test readiness criteria for new approach methods in toxicology: Exemplified for developmental neurotoxicity

Bal-Price A, Hogberg HT, Crofton KM, Daneshian M, FitzGerald RE, Fritsche E, Heinonen T, Hougaard Bennekou S, Klima S, Piersma AH, Sachana M, Shafer TJ, Terron A, Monnet-Tschudi F, Viviani B, Waldmann T, Westerink RHS, Wilks MF, Witters H, Zurich MG, Leist M

ALTEX,  9 Jul 2018


Representing the Process of Inflammation as Key Events in Adverse Outcome Pathways

Villeneuve DL, Landesmann B, Allavena P, Ashley N, Bal-Price A, Corsini E, Halappanavar S, Hussell T, Laskin D, Lawrence T, Nikolic-Paterson D, Pallardy M, Paini A, Pieters R, Roth R, Tschudi-Monnet F

Toxicological Sciences,  1 Jui 2018


Effect of Toxicants on Fatty Acid Metabolism in HepG2 Cells

Grünig D, Duthaler U, Krähenbühl S

Frontiers in Pharmacology,  23 Avr 2018


Mechanisms of toxicity associated with six tyrosine kinase inhibitors in human hepatocyte cell lines

Mingard C, Paech F, Bouitbir J, Krähenbühl S

Journal of Applied Toxicology,  31 Mar 2018


Currently available murine Leydig cell lines can be applied to study early steps of steroidogenesis but not testosterone synthesis

Engeli RT, Fürstenberger C, Kratschmar DV, Odermatt A

Heliyon,  28 Fév 2018


Mechanisms of mitochondrial toxicity of the kinase inhibitors ponatinib, regorafenib and sorafenib in human hepatic HepG2 cells

Paech F, Mingard C, Grünig D, Abegg VF, Bouitbir J, Krähenbühl S

Toxicology,  15 Fév 2018


Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software

Marsousi N, Desmeules JA, Rudaz S, Daali Y

Biopharmaceutics & Drug Disposition,  31 Jan 2018


An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition

Terron A, Bal-Price A, Paini A, Monnet-Tschudi F, Bennekou SH, EFSA WG EPI1 Members, Leist M, Schildknecht S

Archives of Toxicology,  31 Jan 2018


Navigating in vitro bioactivity data: investigating available resources using model compounds

Ilmjarv S, Augsburger F, Tjalling Bolleman J, Liechti R, Bridge A, Sandström J, Jaquet V, Xenarios I, Krause KH

bioRxiv,  17 Jan 2018